FDA approves new diabetes medicationBetter glycemic control may reduce diabetes damageMelissa Healy
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. As a partner of Bejing Peptide, Medicilon provides a full set of preclinical research services for Bejing Peptide semaglutide Injection. ZT002 ...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the
Because it does not need to be injected like other diabetes drugs, this new approval offers those with diabetes a new treatment option. Semaglutide is the first in its class of medications (GLP-1 drugs) that does not need to be injected. “Before this approval, patients did not have an o...
On the other hand, in 2023, FDA approved a groundbreaking therapy for the treatment of type 1 diabetes.Donislecel-jujnis the first allogeneic pancreatic islet cellular therapy obtained from deceased donors’ pancreatic cells, designed to address the challenges faced by diabetic patients unable to co...
aMajor changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. 在葡萄糖新陈代谢上的主要变化,包括新起始糖尿病,在3月内在启蒙或开关之后对非典型抗精神病的...
Patrick Archdeacon, associate director of the Division of Diabetes, Lipid Disorders, and Obesity at the FDA’s Centre for Drug Evaluation and Research, praised the medication. ''Given the challenges many patients experience in achieving their target blood sugar goals,” he said, “[the] approval...
The Food and Drug Administration (FDA) has approved a novel first-in-class drug to treat type 2 diabetes. The drug is called tirzepatide. A person has it as a once-weekly injection under the skin. It has a dual effect, lowering blood sugar and supporting weight loss better than currentl...
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Session...
“incredibly dangerous”. Studies show that losing and regaining weight could increase the risk of conditions such as diabetes. “All of the things we attribute to fatness, like cardiovascular risk, diabetes, depression, anxiety . . . have actually been found to be related to weight ...